Biohaven Ltd. (BHVN)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biohaven Ltd. (“Biohaven” or “the Company”) (NYSE: BHVN). Investors who purchased Biohaven securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Biohaven has violated federal securities laws.
Investigation Details
On March 3, 2025, Biohaven issued a press release reporting its financial results for the fourth quarter and full year 2024, as well as reporting recent business developments. Among other items, Biohaven reported a loss of $1.71 per share for the quarter, while analysts were expecting a loss of only $1.47 per share. The press release also disclosed that recent data from a late-stage study of the Company’s BHV-7000 drug in bipolar mania “did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure”. On this news, Biohaven’s stock price fell $5.12 per share, or 13.77%, to close at $32.06 per share on March 3, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Biohaven securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]